Phase 3 studies point to sustained disease control in patients who remain symptomatic despite standard therapies.

Ultra-long-acting treatment could reshape respiratory care as EU regulators back GSK's high-stakes depemokimab ahead of 2026 ...

GSK’s depemokimab, a long-acting biologic that’s key in the British pharma’s growth plan, has won an endorsement from ...

Among seven new medicines recommended for approval by the EMA's human medicine advisory committee at its latest meeting is ...

Nasal polyps are soft, noncancerous growths on the lining of the nose or sinuses. These growths, while painless, can cause blockages that prevent the sinuses from draining properly. This can make it ...

Europe’s drug regulator backed GSK Plc’s drug to treat severe asthma or a common nasal condition, in the first such recommendation globally for a medicine that is pegged to become a blockbuster.

The digital press release with multimedia content can be accessed here: Basel, June 3, 2019 - Novartis today announced positive topline data from two phase III, multicenter studies evaluating ...

Nasal polyp development, treatment, and recurrence were topics up for discussion in this year’s most popular nasal polyps–related content. Nasal polyp development, treatment, and recurrence, as well ...

Local immunoglobulin levels were found to be significantly higher in polyp tissue specimens, but not in the blood, of patients with nasal polyps. Nasal polyp development may be associated with ...

Aside from inhaled and other steroid delivery methods to treat nasal polyps, are any additional medications available? We have a patient who has had 2 operations and is dealing with on-off steroids.